Ipca Laboratories Limited (BOM: 524494)
India
· Delayed Price · Currency is INR
1,584.25
-9.20 (-0.58%)
At close: Dec 20, 2024
Ipca Laboratories Revenue
Ipca Laboratories had revenue of 23.55B INR in the quarter ending September 30, 2024, with 15.78% growth. This brings the company's revenue in the last twelve months to 85.34B, up 27.75% year-over-year. In the fiscal year ending March 31, 2024, Ipca Laboratories had annual revenue of 77.06B with 23.33% growth.
Revenue (ttm)
85.34B
Revenue Growth
+27.75%
P/S Ratio
n/a
Revenue / Employee
4.92M
Employees
17,335
Market Cap
401.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 77.06B | 14.58B | 23.33% |
Mar 31, 2023 | 62.48B | 4.18B | 7.16% |
Mar 31, 2022 | 58.31B | 4.10B | 7.56% |
Mar 31, 2021 | 54.21B | 7.71B | 16.58% |
Mar 31, 2020 | 46.50B | 8.75B | 23.18% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIpca Laboratories News
- 2 days ago - IPCA Laboratories shares rise over 2% following promoter’s Rs 600 crore stake sale - Business Upturn
- 9 days ago - Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline - Business Upturn
- 4 weeks ago - IPCA Laboratories revises record date to 27th November for Rs. 2 interim dividend - Business Upturn
- 5 weeks ago - IPCA Laboratories shares surge 2% on strong Q2 results - Business Upturn
- 5 weeks ago - IPCA Laboratories Q2 FY25 Results: Revenue up 15.8% YoY to Rs 2,354.90 crore, Net Profit up 57.9% YoY to 229.48 crore - Business Upturn
- 5 weeks ago - Ipca Laboratories Q2 results: Check share price ahead of Q2 results - Business Upturn
- 5 weeks ago - IPCA Laboratories shares decline over 3% ahead of Q2 earnings report - Business Upturn